Loading…
Evaluation of Seroprevalence of Hepatitis A Virus Infection Among Patients With Chronic Hepatitis B Virus Infection/Kronik Hepatit B Virusu Infeksiyonu Olan Hastalarda Hepatit A Virusu Infeksiyonu Seroprevalansinin Degerlendirilmesi
Objective: Patients with chronic hepatitis B virus (HBV) infection that develop a superinfection due to hepatitis A virus (HAV), experience a more severe clinical picture compared to healthy individuals, and their underlying liver disease may exacerbate. Therefore, immunity to HAV should be investig...
Saved in:
Published in: | KLIMIK dergisi 2019-04, Vol.32 (1), p.19 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 1 |
container_start_page | 19 |
container_title | KLIMIK dergisi |
container_volume | 32 |
creator | Alpay, Yesim |
description | Objective: Patients with chronic hepatitis B virus (HBV) infection that develop a superinfection due to hepatitis A virus (HAV), experience a more severe clinical picture compared to healthy individuals, and their underlying liver disease may exacerbate. Therefore, immunity to HAV should be investigated in patients with chronic HBV infection. In this study, it was aimed to investigate HAV serology among patients with chronic HBV infection, and to evaluate for immunization of seronegative cases. Methods: One hundred HBsAg-positive patients were included in the study. HAV serologies of patients with chronic HBV infection were evaluated for susceptibility to HAV infection. Sera were examined with chemiluminescence immunoassay using Architect i1000SR (Abbott Diagnostics, Singapore) analyzer. Statistical analyses were done with IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA). Results: Of patients whose mean age was 44 (range, 20-82) years, 46 (46%) were female and 54 (54%) were male. Anti-HAV IgG was positive in 77 (77%) patients, and negative in 23 (23%) patients. When patients were grouped as under 40 and over 40 years, anti-HAV IgG negativity were 51% and 5%, respectively. Conclusions: Percentage of higher than 50% susceptibility to HAV infection was noteworthy among patients with chronic hepatitis B. Vaccination against hepatitis A should not be neglected for susceptible ones during the follow up of these patients. Key Words: Hepatitis B, hepatitis A, immunization. Amac: Kronik hepatit B virusu (HBV) infeksiyonu olan hastalarda, akut hepatit A virusu (HAV) ile superinfeksiyon gelismesi halinde, saglikli kisilere kiyasla klinik tablo daha agir seyreder ve altta yatan karaciger hastaligini siddetlendirebilir. Bu nedenle kronik HBV infeksiyonu tanisi almis hastalarda, HAV'a karsi bagisiklik durumu arastirilmalidir. Bu calismada kronik HBV infeksiyonu olan hastalarda HAV serolojisininin arastirilmasi ve seronegatif olgularin bagisiklama acisindan degerlendirilmesi amaclanmistir. Yontemler: Calismaya HBsAg-pozitif 100 hasta dahil edilmistir. Kronik HBV infeksiyonu bulunan hastalarin HAV infeksiyonuna karsi duyarliliklari acisindan HAV serolojisi degerlendirilmistir. Serumlar kemiluminesans immunoessey yontemiyle Architect i1000SR (Abbott Diagnostics, Singapur) cihazi kullanilarak incelenmistir. Istatistiksel degerlendirmeler IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package |
doi_str_mv | 10.5152/kd.2019.06 |
format | article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A583990512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A583990512</galeid><sourcerecordid>A583990512</sourcerecordid><originalsourceid>FETCH-LOGICAL-g672-9ced9e394849174f6ceff753ac44ada080c11e0c33ba1ea9a2896d1aedb4ae323</originalsourceid><addsrcrecordid>eNptkM9OwkAQxnvQRIJcfIJNPLfsdvtvjxVRiCSYSNQbGbbTstJuyW4x8Y19DFsUJYaZwyTf_L7JzDjOFaNeyEJ_uMk8nzLh0ejM6TFOmcsC_nrhDKx9o13ENA7CnvM5fodyB42qNalz8oSm3hpsNdQSO2WC27bbKEtS8qzMzpKpzlHuDWlV64I8tn3UjSUvqlmT0drUWskj381_3_ChQzYH5ADs9sTGqo9a78i8BE0mYBsowWTwC6en4L-1QVullSa3WKBpj8iUUWWFVl065zmUFgc_te8s7saL0cSdze-no3TmFlHsu0JiJpCLIAkEi4M8kpjncchBBgFkQBMqGUMqOV8BQxDgJyLKGGC2CgC5z_vO9ffYon3hUum8bgzISlm5TMOEC0FD1lHeCarNDCsla425avUjwxddh5fi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of Seroprevalence of Hepatitis A Virus Infection Among Patients With Chronic Hepatitis B Virus Infection/Kronik Hepatit B Virusu Infeksiyonu Olan Hastalarda Hepatit A Virusu Infeksiyonu Seroprevalansinin Degerlendirilmesi</title><source>Publicly Available Content Database</source><creator>Alpay, Yesim</creator><creatorcontrib>Alpay, Yesim</creatorcontrib><description>Objective: Patients with chronic hepatitis B virus (HBV) infection that develop a superinfection due to hepatitis A virus (HAV), experience a more severe clinical picture compared to healthy individuals, and their underlying liver disease may exacerbate. Therefore, immunity to HAV should be investigated in patients with chronic HBV infection. In this study, it was aimed to investigate HAV serology among patients with chronic HBV infection, and to evaluate for immunization of seronegative cases. Methods: One hundred HBsAg-positive patients were included in the study. HAV serologies of patients with chronic HBV infection were evaluated for susceptibility to HAV infection. Sera were examined with chemiluminescence immunoassay using Architect i1000SR (Abbott Diagnostics, Singapore) analyzer. Statistical analyses were done with IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA). Results: Of patients whose mean age was 44 (range, 20-82) years, 46 (46%) were female and 54 (54%) were male. Anti-HAV IgG was positive in 77 (77%) patients, and negative in 23 (23%) patients. When patients were grouped as under 40 and over 40 years, anti-HAV IgG negativity were 51% and 5%, respectively. Conclusions: Percentage of higher than 50% susceptibility to HAV infection was noteworthy among patients with chronic hepatitis B. Vaccination against hepatitis A should not be neglected for susceptible ones during the follow up of these patients. Key Words: Hepatitis B, hepatitis A, immunization. Amac: Kronik hepatit B virusu (HBV) infeksiyonu olan hastalarda, akut hepatit A virusu (HAV) ile superinfeksiyon gelismesi halinde, saglikli kisilere kiyasla klinik tablo daha agir seyreder ve altta yatan karaciger hastaligini siddetlendirebilir. Bu nedenle kronik HBV infeksiyonu tanisi almis hastalarda, HAV'a karsi bagisiklik durumu arastirilmalidir. Bu calismada kronik HBV infeksiyonu olan hastalarda HAV serolojisininin arastirilmasi ve seronegatif olgularin bagisiklama acisindan degerlendirilmesi amaclanmistir. Yontemler: Calismaya HBsAg-pozitif 100 hasta dahil edilmistir. Kronik HBV infeksiyonu bulunan hastalarin HAV infeksiyonuna karsi duyarliliklari acisindan HAV serolojisi degerlendirilmistir. Serumlar kemiluminesans immunoessey yontemiyle Architect i1000SR (Abbott Diagnostics, Singapur) cihazi kullanilarak incelenmistir. Istatistiksel degerlendirmeler IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, ABD) programiyla yapilmistir. Bulgular: Yas ortalamasi 44 (yas araligi 20-82) olan hastalarin 46 (%46)'si kadin, 54 (%54)'u erkekti. Anti-HAV IgG, 77 (%77) hastada pozitif, 23 (%23) hastada negatifti. Hastalar yaslarina gore ikiye ayrildiginda HAV IgG negatifligi 40 yas altinda %51, 40 yas uzerinde ise %5 olarak saptandi. Sonuclar: Ozellikle 40 yas altindaki kronik hepatit B hastalari arasinda HAV infeksiyonuna duyarliligin %50'nin uzerinde olmasi dikkat cekicidir. Bu hastalarin izlemi sirasinda duyarli bulunan boyle hastalara hepatit A asisinin yapilmasi ihmal edilmemelidir. Anahtar Sozcukler: Hepatit B, hepatit A, bagisiklama.</description><identifier>ISSN: 1301-143X</identifier><identifier>DOI: 10.5152/kd.2019.06</identifier><language>eng</language><publisher>AVES</publisher><subject>Analysis ; Disease susceptibility ; Hepatitis A ; Hepatitis B ; Hepatitis B vaccines ; Hepatitis B virus ; Hepatovirus ; HIV infections ; Immunization ; Immunoglobulin G ; Infection ; Liver ; Medical research ; Patient outcomes ; Prevalence studies (Epidemiology) ; Risk factors ; Vaccination ; Virus diseases</subject><ispartof>KLIMIK dergisi, 2019-04, Vol.32 (1), p.19</ispartof><rights>COPYRIGHT 2019 AVES</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Alpay, Yesim</creatorcontrib><title>Evaluation of Seroprevalence of Hepatitis A Virus Infection Among Patients With Chronic Hepatitis B Virus Infection/Kronik Hepatit B Virusu Infeksiyonu Olan Hastalarda Hepatit A Virusu Infeksiyonu Seroprevalansinin Degerlendirilmesi</title><title>KLIMIK dergisi</title><description>Objective: Patients with chronic hepatitis B virus (HBV) infection that develop a superinfection due to hepatitis A virus (HAV), experience a more severe clinical picture compared to healthy individuals, and their underlying liver disease may exacerbate. Therefore, immunity to HAV should be investigated in patients with chronic HBV infection. In this study, it was aimed to investigate HAV serology among patients with chronic HBV infection, and to evaluate for immunization of seronegative cases. Methods: One hundred HBsAg-positive patients were included in the study. HAV serologies of patients with chronic HBV infection were evaluated for susceptibility to HAV infection. Sera were examined with chemiluminescence immunoassay using Architect i1000SR (Abbott Diagnostics, Singapore) analyzer. Statistical analyses were done with IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA). Results: Of patients whose mean age was 44 (range, 20-82) years, 46 (46%) were female and 54 (54%) were male. Anti-HAV IgG was positive in 77 (77%) patients, and negative in 23 (23%) patients. When patients were grouped as under 40 and over 40 years, anti-HAV IgG negativity were 51% and 5%, respectively. Conclusions: Percentage of higher than 50% susceptibility to HAV infection was noteworthy among patients with chronic hepatitis B. Vaccination against hepatitis A should not be neglected for susceptible ones during the follow up of these patients. Key Words: Hepatitis B, hepatitis A, immunization. Amac: Kronik hepatit B virusu (HBV) infeksiyonu olan hastalarda, akut hepatit A virusu (HAV) ile superinfeksiyon gelismesi halinde, saglikli kisilere kiyasla klinik tablo daha agir seyreder ve altta yatan karaciger hastaligini siddetlendirebilir. Bu nedenle kronik HBV infeksiyonu tanisi almis hastalarda, HAV'a karsi bagisiklik durumu arastirilmalidir. Bu calismada kronik HBV infeksiyonu olan hastalarda HAV serolojisininin arastirilmasi ve seronegatif olgularin bagisiklama acisindan degerlendirilmesi amaclanmistir. Yontemler: Calismaya HBsAg-pozitif 100 hasta dahil edilmistir. Kronik HBV infeksiyonu bulunan hastalarin HAV infeksiyonuna karsi duyarliliklari acisindan HAV serolojisi degerlendirilmistir. Serumlar kemiluminesans immunoessey yontemiyle Architect i1000SR (Abbott Diagnostics, Singapur) cihazi kullanilarak incelenmistir. Istatistiksel degerlendirmeler IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, ABD) programiyla yapilmistir. Bulgular: Yas ortalamasi 44 (yas araligi 20-82) olan hastalarin 46 (%46)'si kadin, 54 (%54)'u erkekti. Anti-HAV IgG, 77 (%77) hastada pozitif, 23 (%23) hastada negatifti. Hastalar yaslarina gore ikiye ayrildiginda HAV IgG negatifligi 40 yas altinda %51, 40 yas uzerinde ise %5 olarak saptandi. Sonuclar: Ozellikle 40 yas altindaki kronik hepatit B hastalari arasinda HAV infeksiyonuna duyarliligin %50'nin uzerinde olmasi dikkat cekicidir. Bu hastalarin izlemi sirasinda duyarli bulunan boyle hastalara hepatit A asisinin yapilmasi ihmal edilmemelidir. Anahtar Sozcukler: Hepatit B, hepatit A, bagisiklama.</description><subject>Analysis</subject><subject>Disease susceptibility</subject><subject>Hepatitis A</subject><subject>Hepatitis B</subject><subject>Hepatitis B vaccines</subject><subject>Hepatitis B virus</subject><subject>Hepatovirus</subject><subject>HIV infections</subject><subject>Immunization</subject><subject>Immunoglobulin G</subject><subject>Infection</subject><subject>Liver</subject><subject>Medical research</subject><subject>Patient outcomes</subject><subject>Prevalence studies (Epidemiology)</subject><subject>Risk factors</subject><subject>Vaccination</subject><subject>Virus diseases</subject><issn>1301-143X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptkM9OwkAQxnvQRIJcfIJNPLfsdvtvjxVRiCSYSNQbGbbTstJuyW4x8Y19DFsUJYaZwyTf_L7JzDjOFaNeyEJ_uMk8nzLh0ejM6TFOmcsC_nrhDKx9o13ENA7CnvM5fodyB42qNalz8oSm3hpsNdQSO2WC27bbKEtS8qzMzpKpzlHuDWlV64I8tn3UjSUvqlmT0drUWskj381_3_ChQzYH5ADs9sTGqo9a78i8BE0mYBsowWTwC6en4L-1QVullSa3WKBpj8iUUWWFVl065zmUFgc_te8s7saL0cSdze-no3TmFlHsu0JiJpCLIAkEi4M8kpjncchBBgFkQBMqGUMqOV8BQxDgJyLKGGC2CgC5z_vO9ffYon3hUum8bgzISlm5TMOEC0FD1lHeCarNDCsla425avUjwxddh5fi</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Alpay, Yesim</creator><general>AVES</general><scope/></search><sort><creationdate>20190401</creationdate><title>Evaluation of Seroprevalence of Hepatitis A Virus Infection Among Patients With Chronic Hepatitis B Virus Infection/Kronik Hepatit B Virusu Infeksiyonu Olan Hastalarda Hepatit A Virusu Infeksiyonu Seroprevalansinin Degerlendirilmesi</title><author>Alpay, Yesim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g672-9ced9e394849174f6ceff753ac44ada080c11e0c33ba1ea9a2896d1aedb4ae323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Analysis</topic><topic>Disease susceptibility</topic><topic>Hepatitis A</topic><topic>Hepatitis B</topic><topic>Hepatitis B vaccines</topic><topic>Hepatitis B virus</topic><topic>Hepatovirus</topic><topic>HIV infections</topic><topic>Immunization</topic><topic>Immunoglobulin G</topic><topic>Infection</topic><topic>Liver</topic><topic>Medical research</topic><topic>Patient outcomes</topic><topic>Prevalence studies (Epidemiology)</topic><topic>Risk factors</topic><topic>Vaccination</topic><topic>Virus diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alpay, Yesim</creatorcontrib><jtitle>KLIMIK dergisi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alpay, Yesim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Seroprevalence of Hepatitis A Virus Infection Among Patients With Chronic Hepatitis B Virus Infection/Kronik Hepatit B Virusu Infeksiyonu Olan Hastalarda Hepatit A Virusu Infeksiyonu Seroprevalansinin Degerlendirilmesi</atitle><jtitle>KLIMIK dergisi</jtitle><date>2019-04-01</date><risdate>2019</risdate><volume>32</volume><issue>1</issue><spage>19</spage><pages>19-</pages><issn>1301-143X</issn><abstract>Objective: Patients with chronic hepatitis B virus (HBV) infection that develop a superinfection due to hepatitis A virus (HAV), experience a more severe clinical picture compared to healthy individuals, and their underlying liver disease may exacerbate. Therefore, immunity to HAV should be investigated in patients with chronic HBV infection. In this study, it was aimed to investigate HAV serology among patients with chronic HBV infection, and to evaluate for immunization of seronegative cases. Methods: One hundred HBsAg-positive patients were included in the study. HAV serologies of patients with chronic HBV infection were evaluated for susceptibility to HAV infection. Sera were examined with chemiluminescence immunoassay using Architect i1000SR (Abbott Diagnostics, Singapore) analyzer. Statistical analyses were done with IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, USA). Results: Of patients whose mean age was 44 (range, 20-82) years, 46 (46%) were female and 54 (54%) were male. Anti-HAV IgG was positive in 77 (77%) patients, and negative in 23 (23%) patients. When patients were grouped as under 40 and over 40 years, anti-HAV IgG negativity were 51% and 5%, respectively. Conclusions: Percentage of higher than 50% susceptibility to HAV infection was noteworthy among patients with chronic hepatitis B. Vaccination against hepatitis A should not be neglected for susceptible ones during the follow up of these patients. Key Words: Hepatitis B, hepatitis A, immunization. Amac: Kronik hepatit B virusu (HBV) infeksiyonu olan hastalarda, akut hepatit A virusu (HAV) ile superinfeksiyon gelismesi halinde, saglikli kisilere kiyasla klinik tablo daha agir seyreder ve altta yatan karaciger hastaligini siddetlendirebilir. Bu nedenle kronik HBV infeksiyonu tanisi almis hastalarda, HAV'a karsi bagisiklik durumu arastirilmalidir. Bu calismada kronik HBV infeksiyonu olan hastalarda HAV serolojisininin arastirilmasi ve seronegatif olgularin bagisiklama acisindan degerlendirilmesi amaclanmistir. Yontemler: Calismaya HBsAg-pozitif 100 hasta dahil edilmistir. Kronik HBV infeksiyonu bulunan hastalarin HAV infeksiyonuna karsi duyarliliklari acisindan HAV serolojisi degerlendirilmistir. Serumlar kemiluminesans immunoessey yontemiyle Architect i1000SR (Abbott Diagnostics, Singapur) cihazi kullanilarak incelenmistir. Istatistiksel degerlendirmeler IBM SPSS Statistics for Windows. Version 20.0 (Statistical Package for the Social Sciences, IBM Corp., Armonk, NY, ABD) programiyla yapilmistir. Bulgular: Yas ortalamasi 44 (yas araligi 20-82) olan hastalarin 46 (%46)'si kadin, 54 (%54)'u erkekti. Anti-HAV IgG, 77 (%77) hastada pozitif, 23 (%23) hastada negatifti. Hastalar yaslarina gore ikiye ayrildiginda HAV IgG negatifligi 40 yas altinda %51, 40 yas uzerinde ise %5 olarak saptandi. Sonuclar: Ozellikle 40 yas altindaki kronik hepatit B hastalari arasinda HAV infeksiyonuna duyarliligin %50'nin uzerinde olmasi dikkat cekicidir. Bu hastalarin izlemi sirasinda duyarli bulunan boyle hastalara hepatit A asisinin yapilmasi ihmal edilmemelidir. Anahtar Sozcukler: Hepatit B, hepatit A, bagisiklama.</abstract><pub>AVES</pub><doi>10.5152/kd.2019.06</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1301-143X |
ispartof | KLIMIK dergisi, 2019-04, Vol.32 (1), p.19 |
issn | 1301-143X |
language | eng |
recordid | cdi_gale_infotracmisc_A583990512 |
source | Publicly Available Content Database |
subjects | Analysis Disease susceptibility Hepatitis A Hepatitis B Hepatitis B vaccines Hepatitis B virus Hepatovirus HIV infections Immunization Immunoglobulin G Infection Liver Medical research Patient outcomes Prevalence studies (Epidemiology) Risk factors Vaccination Virus diseases |
title | Evaluation of Seroprevalence of Hepatitis A Virus Infection Among Patients With Chronic Hepatitis B Virus Infection/Kronik Hepatit B Virusu Infeksiyonu Olan Hastalarda Hepatit A Virusu Infeksiyonu Seroprevalansinin Degerlendirilmesi |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A49%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Seroprevalence%20of%20Hepatitis%20A%20Virus%20Infection%20Among%20Patients%20With%20Chronic%20Hepatitis%20B%20Virus%20Infection/Kronik%20Hepatit%20B%20Virusu%20Infeksiyonu%20Olan%20Hastalarda%20Hepatit%20A%20Virusu%20Infeksiyonu%20Seroprevalansinin%20Degerlendirilmesi&rft.jtitle=KLIMIK%20dergisi&rft.au=Alpay,%20Yesim&rft.date=2019-04-01&rft.volume=32&rft.issue=1&rft.spage=19&rft.pages=19-&rft.issn=1301-143X&rft_id=info:doi/10.5152/kd.2019.06&rft_dat=%3Cgale%3EA583990512%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g672-9ced9e394849174f6ceff753ac44ada080c11e0c33ba1ea9a2896d1aedb4ae323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A583990512&rfr_iscdi=true |